InsiderSignal.AI

InsiderSignal.ai

KALV - Kalvista Pharmaceuticals, Inc.

Insider Sale by Sweeny Nicole (Chief Commercial Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Sweeny Nicole, serving as Chief Commercial Officer at Kalvista Pharmaceuticals, Inc. (KALV), sold 1,862 shares at $20.22 per share, for a total transaction value of $37,643.00. Following this transaction, Sweeny Nicole now holds 51,391 shares of KALV.

This sale represents a 3.00% decrease in Sweeny Nicole's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, April 17, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 20, 2026, 3 days after the trade was made.

Kalvista Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Sweeny Nicole

Chief Commercial Officer

Nicole Sweeny is the Chief Commercial Officer at KalVista Pharmaceuticals, Inc. (KALV), where she leverages over 20 years of experience in commercial strategy and leadership in rare diseases.[[1]](https://www.kalvista.com/about/senior-management/nicole-sweeny/)[[5]](https://firstwordpharma.com/story/5764160) She holds a BS in Marketing from the Carroll School of Management at Boston College.[[1]](https://www.kalvista.com/about/senior-management/nicole-sweeny/) Prior to KalVista, Sweeny served as Chief Commercial Officer at Praxis Precision Medicines, leading commercial strategy for global launches in CNS conditions. She was US Franchise Head for Hereditary Angioedema (HAE) at Takeda Pharmaceuticals, overseeing the US launch of Takhzyro®, the market-leading HAE prophylaxis treatment. Earlier, at Shire Pharmaceuticals, she advanced through roles in marketing, sales, and product strategy for HAE products including Cinryze®, Firazyr®, and Kalbitor®, and served as Global Product Strategy Lead for Hemophilia.[[1]](https://www.kalvista.com/about/senior-management/nicole-sweeny/)

View full insider profile →

Trade Price

$20.22

Quantity

1,862

Total Value

$37,643.00

Shares Owned

51,391

Trade Date

Friday, April 17, 2026

4 days ago

SEC Filing Date

Monday, April 20, 2026

Filed 3 days after trade

HEALTHCAREBIOTECHNOLOGY

About Kalvista Pharmaceuticals, Inc.

Company Overview

No company information available
View news mentioning KALV

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5810446

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime